Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Alumis Inc. (ALMS:NASDAQ), powered by AI.
Alumis Inc. is currently trading at $24.15. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Alumis Inc. on Alpha Lenz.
View Alumis Inc.'s valuation metrics on Alpha Lenz.
“Alumis Inc.'s ROE is -86.7%. Explore profitability and growth together.”
Ask for details →Alumis Inc. operates as a biopharmaceutical company that focuses on the research, development, and commercialization of novel therapeutic solutions. Concentrating primarily on autoimmune diseases, Alumis Inc. aims to address unmet medical needs within this challenging sector. The company's approach involves leveraging advanced scientific techniques to innovate targeted treatments, seeking to improve patient outcomes and quality of life. By collaborating with leading researchers and leveraging cutting-edge technologies, Alumis Inc. is at the forefront of medical advancements. In the broader healthcare market, Alumis Inc. plays a critical role as it approaches autoimmune disorders with a distinct methodology, contributing to the diversity and robustness of treatment options available. Known for its commitment to fostering innovation and enhancing therapeutic efficacy, Alumis Inc. continues to impact the biopharmaceutical landscape by delivering promising solutions to complex health issues.
“Alumis Inc.'s ROE is -86.7%. Explore profitability and growth together.”
Ask for details →Alumis Inc. (ticker: ALMS) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 225 employees.
The current price is $24.15 with a P/E ratio of -x and P/B of -x.
ROE is -86.69% and operating margin is -1886.92%. Annual revenue is $24M.